Omalizumab: profile and news

Tanox Reports 2006 First Quarter Results May 2, 2006
Net royalty revenue from sales of Xolair(R) (omalizumab) was $8.8 million for the first quarter of 2006, compared to Xolair royalty revenue of $5.9 million for ... - MSN Money

New drug offers relief for those with allergic asthma May 10, 2006
...much-needed relief. Unlike other meds, Xolair (omalizumab) is injected and doesn't just control asthma's symptoms. It actually shuts ... - News 14 Carolina,

Allergic asthma May 10, 2006
Unlike other meds, Xolair (omalizumab) is injected and doesn't just control asthma's symptoms. It actually shuts off the allergic ... - News 14 Carolina,

The facts about asthma May 2, 2006
...of asthma. A recent breakthrough has been the omalizumab jab, which is effective for those with the most severe symptoms. For asthma ... - Daily Mail - UK,

Tanox Reports 48-Week Results From TNX-355 Phase 2 Clinical Trial May 2, 2006
Tanox's first- approved drug, Xolair® (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. ... - Yahoo! News (press release)

(PRN) Tanox to Present at Two Investor Conferences in May Apr 17, 2006
Tanox's first- approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed allergic asthma. ... - Houston Chronicle,

Fibrogen, Astellas Anemia Deal: $300M, Plus $465M In Milestones Apr 28, 2006
...three-way collaboration with Basel, Switzerland-based Novartis AG and Genentech Inc., of South San Francisco, for the asthma drug Xolair (omalizumab) and other ... - BioWorld Online (subscription),

Other information

Indication
For treatment of asthma caused by allergies

Pharmacology
Xolair inhibits the binding of IgE to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils. Reduction in surface-bound IgE on FceRI-bearing cells limits the degree of release of mediators of the allergic response. Xolair is used to treat severe, persisten asthma.

Mechanism Of Action
Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.

Drug Category
Immunomodulatory Agents; Anti-Asthmatic Agents; unclassified therapeutic agents (92:00.00)

Brand Names/Synonyms
Ig gamma-1 chain C region; Xolair (Genentech Inc)

Dosage Forms
POWDER FOR SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Humanized anti-IgE antibody

Chemical Formula
C6450H9916N1714O2023S38 >Anti IgE antibody VL domain chain 1 >Anti IgE antibody VH domain chain 2 >Anti IgE antibody VL domain chain 2

Half Life
26 days

Drug Type
Approved Drug

# Accession No
BIOD00081

CAS Registry Number
242138-07-4